@article{cce3be7209c04be6b1535f4ef7911365,
title = "Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker",
abstract = "Elevated serum lactate dehydrogenase (sLDH) is associated with poor clinical outcomes in patients with stage IV metastatic melanoma (MM). It is currently unknown if sLDH elevation correlates with distinct molecular, metabolic, or immune features of melanoma metastases. The identification of such features may identify rational therapeutic strategies for patients with elevated sLDH. Thus, we obtained sLDH levels for melanoma patients with metastases who had undergone molecular and/or immune profiling. Our analysis of multi-omics data from independent cohorts of melanoma metastases showed that elevated sLDH was not significantly associated with differences in immune cell infiltrate, point mutations, DNA copy number variations, promoter methylation, RNA expression, or protein expression in melanoma metastases. The only significant association observed for elevated sLDH was with the number of metastatic sites of disease. Our data support that sLDH correlates with disease burden, but not specific molecular or immunological phenotypes, in metastatic melanoma.",
keywords = "melanoma, molecular profiling, serum lactate dehydrogenase, tumor immunity, tumor metabolism",
author = "Fischer, {Grant M.} and Carapeto, {Fernando C.L.} and Joon, {Aron Y.} and Haydu, {Lauren E.} and Huiqin Chen and Fuchenchu Wang and {Van Arnam}, {John S.} and McQuade, {Jennifer L.} and Khalida Wani and Kirkwood, {John M.} and Thompson, {John F.} and Tetzlaff, {Michael T.} and Lazar, {Alexander J.} and Tawbi, {Hussein A.} and Gershenwald, {Jeffrey E.} and Scolyer, {Richard A.} and Long, {Georgina V.} and Davies, {Michael A.}",
note = "Funding Information: GMF received research funding from the NIH National Center for Advancing Translational Sciences (TL1TR000369 and UL1TR000371) and The University of Texas MD Anderson Cancer Center (MD Anderson)/UTHealth Graduate School of Biomedical Sciences{\textquoteright} Caroline Ross Fellowship, Schissler Foundation Fellowship, and Presidents{\textquoteright} Research Scholarship. MAD is supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI (R01 CA121118‐06A1 and 2T32CA009666‐21), the Cancer Prevention Research Institute of Texas (CPRIT) (RP170401 and RP160183), the MD Anderson Multidisciplinary Research Program, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. AJL is supported by the MD Anderson Melanoma Moon Shots Program and the NIH Melanoma SPORE (P50CA221703). JEG is supported by the Robert and Lynne Grossman Family Foundation, the Michael and Patricia Booker Melanoma Research Endowment, the NIH SPORE grant in melanoma at MD Anderson (P50CA221703), and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. GVL and JFT are supported by the Sydney Medical School Foundation of the University of Sydney. RAS and GVL are supported by Australian National Health and Medical Research Council Practitioner Fellowships. Funding Information: MAD has been a consultant to Roche/Genentech, Array, Novartis, BMS, GSK, Sanofi‐Aventis, and Vaccinex, and he has been the PI of funded research grants to his institution by Roche/Genentech, GSK, Sanofi‐Aventis, Merck, Myriad, and Oncothyreon. MTT has served on advisory committees for Novartis, Myriad Genetics, and Seattle Genetics. AJL has served on advisory committees and/or scientific advisory boards for BMS, GSK/Novartis, Roche/Genentech, MedImmune/AstraZeneca, Bayer, Guardant and ArcherDX. JEG has served on advisory committees and/or scientific advisory boards for Merck, Novartis, and Syndax. HAT has been a consultant to Roche/Genentech, Array, Novartis, BMS, Merck, and he has been the PI of funded research grants to his institution by Roche/Genentech, Novartis, BMS, Merck, GSK, and Celgene. RAS has received fees for professional services from Merck Sharp & Dohme, GlaxoSmithKline Australia, Bristol‐Myers Squibb, Dermpedia, Novartis Pharmaceuticals Australia Pty Ltd, Myriad, NeraCare, and Amgen. No potential conflicts of interest were disclosed by the other authors. Funding Information: GMF received research funding from the NIH National Center for Advancing Translational Sciences (TL1TR000369 and UL1TR000371) and The University of Texas MD Anderson Cancer Center (MD Anderson)/UTHealth Graduate School of Biomedical Sciences? Caroline Ross Fellowship, Schissler Foundation Fellowship, and Presidents? Research Scholarship. MAD is supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI (R01 CA121118-06A1 and 2T32CA009666-21), the Cancer Prevention Research Institute of Texas (CPRIT) (RP170401 and RP160183), the MD Anderson Multidisciplinary Research Program, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. AJL is supported by the MD Anderson Melanoma Moon Shots Program and the NIH Melanoma SPORE (P50CA221703). JEG is supported by the Robert and Lynne Grossman Family Foundation, the Michael and Patricia Booker Melanoma Research Endowment, the NIH SPORE grant in melanoma at MD Anderson (P50CA221703), and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. GVL and JFT are supported by the Sydney Medical School Foundation of the University of Sydney. RAS and GVL are supported by Australian National Health and Medical Research Council Practitioner Fellowships. The authors thank the following from MD Anderson for data collection: Brandy Conner, Courtney Hudgens, and Bhavana Singh. The authors also thank colleagues from Melanoma Institute Australia and the Royal Prince Alfred Hospital for assistance. Publisher Copyright: {\textcopyright} 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2020",
month = nov,
doi = "10.1002/cam4.3474",
language = "English (US)",
volume = "9",
pages = "8650--8661",
journal = "Cancer medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Inc.",
number = "22",
}